Mangalam Drugs and Organics Ltd's Q3FY25 Quarter Results
- 14 Feb 2025
Result Summary
- Mangalam Drugs and Organics Ltd reported a 11.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 8.7%.
- Its expenses for the quarter were up by 10.9% QoQ and down 10.1% YoY.
- The net profit decreased 52.0% QoQ and increased 158.0% YoY.
- The earnings per share (EPS) of Mangalam Drugs and Organics Ltd stood at 0.8 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 88.85 | 80.08 | 97.34 | 11.0% | -8.7% |
Total Expenses | 87.48 | 78.88 | 97.30 | 10.9% | -10.1% |
Profit Before Tax | 1.37 | 1.20 | 0.04 | 14.2% | 3325.0% |
Tax | 0.08 | -1.49 | -0.46 | -105.4% | -117.4% |
Profit After Tax | 1.29 | 2.69 | 0.50 | -52.0% | 158.0% |
Earnings Per Share | 0.80 | 1.70 | 0.30 | -52.9% | 166.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Mangalam Drugs and Organics Ltd is a company involved in the manufacture and sale of pharmaceuticals and chemical products. It operates within the pharmaceutical industry, focusing on products such as Active Pharmaceutical Ingredients (APIs) and intermediates. The company is known for its contribution to healthcare through the production of essential drugs that cater to various therapeutic categories. While specific recent developments for Mangalam Drugs and Organics Ltd are not provided in the data, the company typically engages in expanding its product portfolio and enhancing its manufacturing capabilities to meet global standards and cater to the increasing demand for pharmaceutical products.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Mangalam Drugs and Organics Ltd reported a total income of ₹88.85 crores. This represents an 11.0% increase from the previous quarter (Q2FY25), where the total income was ₹80.08 crores. However, when compared to the same quarter in the previous fiscal year (Q3FY24), there is an 8.7% decrease, as the total income then was ₹97.34 crores. These figures highlight the company's revenue performance over the specified periods, reflecting both quarter-over-quarter growth and year-over-year decline.
Profitability
During Q3FY25, the company achieved a profit before tax of ₹1.37 crores, which marks a 14.2% increase from Q2FY25's profit before tax of ₹1.20 crores. When compared to Q3FY24, where the profit before tax was a mere ₹0.04 crores, there is a significant year-over-year increase of 3325.0%. However, the profit after tax for Q3FY25 was ₹1.29 crores, down by 52.0% from the previous quarter's ₹2.69 crores, but up by 158.0% from the same quarter last year, where it was ₹0.50 crores. The earnings per share followed a similar pattern, decreasing by 52.9% quarter-over-quarter from ₹1.70 to ₹0.80, yet increasing year-over-year by 166.7% from ₹0.30.
Operating Metrics
The total expenses for Q3FY25 were ₹87.48 crores, an increase of 10.9% from Q2FY25's expenses of ₹78.88 crores. Compared to Q3FY24, the total expenses decreased by 10.1% from ₹97.30 crores. The tax component for Q3FY25 was ₹0.08 crores, a notable change from the previous quarter where there was a tax rebate of ₹-1.49 crores, and a shift from Q3FY24's tax rebate of ₹-0.46 crores. These operating metrics provide a detailed view of the company's financial activities and the changes in tax obligations over time.
